BIIB091 clinical trials
Also written BIIB091.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses BIIB091 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BIIB091
- 5
Studies by the year they started
6 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2023 | 1 |
| 2024 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses BIIB091 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)CompletedPhase 2BiogenNCT05798520Written as BIIB091How we know
- A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy ParticipantsCompletedPhase 1BiogenNCT06574828Written as BIIB091How we know
- A Study to Find Out How Different Forms of BIIB091 is Processed in The Body With and Without Food in Healthy ParticipantsCompletedPhase 1BiogenNCT06640933Written as BIIB091How we know
- A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male ParticipantsCompletedPhase 1BiogenNCT06311786Written as [14C]-BIIB091How we know
- Study of BIIB091 Formulations in Healthy ParticipantsCompletedPhase 1BiogenNCT04564612Written as BIIB091How we know
- A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult ParticipantsCompletedPhase 1BiogenNCT03943056Written as BIIB091How we know